Clinical Trial Update: Carboplatin, Nab-Paclitaxel and Pembrolizumab for Metastatic Triple-Negative Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial of carboplatin, nab-paclitaxel, and pembrolizumab in metastatic triple-negative breast cancer completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Triple-negative Breast Cancer

Drugs mentioned

• CARBOPLATIN (Carboplatin)
• Nab-paclitaxel (paclitaxel protein-bound)
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Case Comprehensive Cancer Center | Conditions: Metastatic Triple Negative Breast Cancer | Phase 2 | Status: COMPLETED | Results posted: 2023-10-06